Work

Internalization of Angiotensin-(1–12) in Adult Retinal Pigment Epithelial-19 Cells

Year: 2023

Type: article

Abstract: Purpose: Angiotensin-(1–12) [Ang-(1–12)] serves as a primary substrate to generate angiotensin II (Ang II) by angiotensin-converting enzyme and/or chymase suggests it may be an unrecognized source of Ang II-mediated microvascular complication in hypertension-mediated retinopathy. We investigated Ang-(1–12) expression and internalization in adult retinal pigment epithelial-19 (ARPE-19) cultured cells. We performed the internalization of Ang-(1–12) in ARPE-19 cells in the presence of a highly specific monoclonal antibody (mAb) developed against the C-terminal end of the Ang-(1–12) sequence. Methods: All experiments were performed in confluent ARPE-19 cells (passage 28–35). We employed high-performance liquid chromatography to purify radiolabeled, 125 I-Ang-(1–12) and immuno-neutralization with Ang-(1–12) mAb to demonstrate Ang-(1–12)'s internalization in ARPE-19 cells. Internalization was also demonstrated by immunofluorescence (IF) method. Results: These procedures revealed internalization of an intact 125 I-Ang-(1–12) in ARPE-19 cells. A significant reduction (∼53%, P < 0.0001) in 125 I-Ang-(1–12) internalization was detected in APRE-19 cells in the presence of the mAb. IF staining experiments further confirms internalization of Ang-(1–12) into the cells from the extracellular culture medium. No endogenous expression was detected in the ARPE-19 cells. An increased intensity of IF staining was detected in cells exposed to 1.0 μM Ang-(1–12) compared with 0.1 μM. Furthermore, we found hydrolysis of Ang-(1–12) into Ang II by ARPE-19 cells' plasma membranes. Conclusions: Intact Ang-(1–12) peptide is internalized from the extracellular spaces in ARPE-19 cells and metabolized into Ang II. The finding that a selective mAb blocks cellular internalization of Ang-(1–12) suggests alternate therapeutic approaches to prevent/reduce the RPE cells Ang II burden.

Source: Journal of Ocular Pharmacology and Therapeutics

DOI: 10.1089/jop.2022.0139